Adenis A, Mazard T, Fraisse J, Chalbos P, et al. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as
first line therapy in patients with unresectable RAS-mutated metastatic
colorectal cancer. BMC Cancer 2021;21:564.
PMID: 34001059